99071-54-2

Basic information

• Product Name: 6-Aminomethylquinoline
• Synonyms: 6-AMINOMETHYLQUINOLINE;ART-CHEM-BB B016095;6-Quinolinemethanamine;QUINOLINE-6-YLMETHANAMINE;6-Methylaminoquinoline;(quinolin-6-ylmethyl)amine;1-quinolin-6-ylmethanamine;(quinolin-6-ylmethyl)amine(SALTDATA: 2HCl)
• CAS NO: 99071-54-2
• Molecular Formula: C₁₀H₁₀N₂
• Molecular Weight: 158.2
• Product Categories: Amines and Anilines;Heterocycles;pharmacetical;Quinoline
• Mol File: 99071-54-2.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 159°C/2mmHg(lit.)
• Flash Point: 169.9 °C
• Appearance: /Solid
• Density: 1.156 g/cm³
• Vapor Pressure: 0.000458mmHg at 25°C
• Refractive Index: 1.6410-1.6450
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 8.68±0.30(Predicted)
• CAS DataBase Reference: 6-Aminomethylquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Aminomethylquinoline(99071-54-2)
• EPA Substance Registry System: 6-Aminomethylquinoline(99071-54-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 99071-54-2(Hazardous Substances Data)

Usage

Description

6-Aminomethylquinoline, also known as 6-Quinolinemethanamine, is an organic compound with the chemical formula C10H9N. It is a derivative of quinoline, featuring an aminomethyl group attached to the 6th position of the quinoline ring. 6-Aminomethylquinoline is known for its potential applications in the pharmaceutical and chemical industries due to its unique chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
6-Aminomethylquinoline is used as a reagent in the synthesis of novel 7-[(quinolin-6-yl)methyl] purines, which are potential c-Met inhibitors. These inhibitors are of interest in the development of targeted therapies for various cancers, as they can help regulate the activity of the c-Met receptor tyrosine kinase, a key player in tumor growth and progression.
In the synthesis process, 6-Aminomethylquinoline serves as a key intermediate, providing a platform for the attachment of various functional groups to create the desired purine-based c-Met inhibitors. The development of these inhibitors can contribute to the advancement of cancer treatment options, offering more targeted and effective therapies for patients.
Overall, 6-Aminomethylquinoline plays a significant role in the pharmaceutical industry, particularly in the development of novel compounds with potential therapeutic applications. Its unique structure and reactivity make it a valuable component in the synthesis of various bioactive molecules, paving the way for new discoveries and innovations in medicine.

InChI:InChI=1/C10H10N2/c11-7-8-3-4-10-9(6-8)2-1-5-12-10/h1-6H,7,11H2

Upstream product

• 426265-40-9 quinolin-6-yl 4-methylbenzene-1-sulfonate 
• 173089-80-0 quinolin-6-yl triflate 
• 580-16-5 6-hydroxyquinoline 
• 5332-25-2 6-bromoquinoline 
• 612-57-7 6-chloroquinoline 
• 1092513-18-2 quinolin-6-yl methanesulfonate 
• 5382-43-4 quinoline-6-carboxamide 
• 10349-57-2 Quinoline-6-carboxylic acid 
• 150-13-0 4-amino-benzoic acid 
• 23395-72-4 quinoline-6-carbonitrile 
• 38896-30-9 6-(methoxycarbonyl)quinoline 
• 100516-88-9 6-(hydroxymethyl)quinoline 
• 872047-71-7 2-(quinolin-6-ylmethyl)isoindoline-1,3-dione 
• 7732-18-5 water 

Downstream Products

• 956907-14-5 6-((6-bromo-1H-[1,2,3]triazolo[4,5-b]pyrazine-1-yl)methyl)quinoline 
• 1459731-02-2 N-(2-amino-2-oxoethyl)-4-(3-(quinolin-7-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 
• 1459732-34-3 6-((5-(4-carbamoyl-3,5-difluorophenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline 1-oxide 
• 1350427-59-6 2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 
• 1459732-36-5 2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 2,2,2-trifluoroacetate 
• 1459732-37-6 2-chloro-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 
• 1459732-38-7 2,6-difluoro-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 
• 1350428-31-7 2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamide 
• 1459732-41-2 2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamide hydrochloride 
• 1459732-49-0 2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)benzamide 2,2,2-trifluoroacetate 
• 1459732-54-7 4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-2-trifluoromethyl-benzamide 
• 1350426-27-5 methyl 4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]-triazolo[4,5-b]pyridin-5-yl)benzoate 
• 1350426-28-6 4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]-triazolo[4,5-b]pyridin-5-yl)benzoic acid 
• 1350427-57-4 methyl 2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]-triazolo[4,5-b]pyridin-5-yl)benzoate 

Relevant articles and documents

Selective Hydrogenation of Nitriles to Primary Amines by using a Cobalt Phosphine Catalyst

A general procedure for the catalytic hydrogenation of nitriles to primary amines by using a non-noble metal-based system is presented. Co(acac)3 in combination with tris[2-(dicyclohexylphosphino)ethyl]phosphine efficiently catalyzes the selective hydrogenation of a wide range of (hetero)aromatic and aliphatic nitriles to give the corresponding amines.

Quinoline compounds and preparation method thereof, and intermediate, pharmaceutical composition and application of quinoline compounds

The invention discloses quinoline compounds and a preparation method thereof, and an intermediate, a pharmaceutical composition and application of quinoline compounds. The invention provides quinoline compounds disclosed as Formula 1, and pharmaceutically acceptable salts, solvates, metabolites, metabolism precursors or pharmaceutical precursors thereof. The quinoline compounds have favorable inhibitory effects on tyrosine kinase C-Met, and can be used for preparing drugs for prevention, treatment or auxiliary treatment on multiple diseases related to C-Met expression or activity, and especially neoplastic diseases.

6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY

PROBLEM TO BE SOLVED: To provide 6-O-substituted ketolides with antibacterial activity, having acid stability and enhanced activity toward gram negative bacteria and macrolide resistant gram positive bacteria. SOLUTION: This invention provides 6-O-substituted erythromycin ketolide derivatives such as formula (II) and compositions comprising the compounds. [Y and Z together form a group X; X is ketone, hydroxyimino or the like; or, one of Y and Z is H and the other is hydrogen, hydroxy or the like; Ra is H, hydroxy; Rc is H or a hydroxy protective group; R is a substituted methyl group]. COPYRIGHT: (C)2015,JPOandINPIT